Evidence map›Paper›PMID 38302908›Full record

ArticleBMC ophthalmology2024

Implementing and evaluating a fully functional AI-enabled model for chronic eye disease screening in a real clinical environment.

Christos Skevas, Nicolás Pérez de Olaguer, Albert Lleó, David Thiwa, Ulrike Schroeter, Inês Valente Lopes, Luca Mautone, Stephan J Linke, Martin Stephan Spitzer, Daniel Yap and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Christos SkevasDepartment of Ophthalmology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, 20249, Hamburg, Germany.
Nicolás Pérez de OlaguerTeleMedC GmbH, Raboisen 32, 20095, Hamburg, Germany.
Albert LleóTeleMedC GmbH, Raboisen 32, 20095, Hamburg, Germany.
David ThiwaDepartment of Otorhinolaryngology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, 20249, Hamburg, Germany.
Ulrike SchroeterDepartment of Ophthalmology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, 20249, Hamburg, Germany.
Inês Valente LopesDepartment of Ophthalmology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, 20249, Hamburg, Germany. i.lopes@uke.de.
Luca MautoneDepartment of Ophthalmology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, 20249, Hamburg, Germany.
Stephan J LinkeZentrum Sehestaerke, Martinistraße 64, 20251, Hamburg, Germany.
Martin Stephan SpitzerDepartment of Ophthalmology, University Medical Center Hamburg - Eppendorf, Martinistr. 52, 20249, Hamburg, Germany.
Daniel YapTeleMedC Pty Ltd, 61 Ubi Avenue 1, #06-11 UBPoint, Singapore, 40894, Singapore.
Di XiaoTeleMedC Pty Ltd, Brisbane Technology Park, Level 2, 1 Westlink Court, Darra, QLD 4076, Australia.
University Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArtificial intelligence (AI) has the potential to increase the affordability and accessibility of eye disease screening, especially with the recent approval of AI-based diabetic retinopathy (DR) screening programs in several countries.

methodsThis study investigated the performance, feasibility, and user experience of a seamless hardware and software solution for screening chronic eye diseases in a real-world clinical environment in Germany. The solution integrated AI grading for DR, age-related macular degeneration (AMD), and glaucoma, along with specialist auditing and patient referral decision. The study comprised several components: (1) evaluating the entire system solution from recruitment to eye image capture and AI grading for DR, AMD, and glaucoma; (2) comparing specialist's grading results with AI grading results; (3) gathering user feedback on the solution.

resultsA total of 231 patients were recruited, and their consent forms were obtained. The sensitivity, specificity, and area under the curve for DR grading were 100.00%, 80.10%, and 90.00%, respectively. For AMD grading, the values were 90.91%, 78.79%, and 85.00%, and for glaucoma grading, the values were 93.26%, 76.76%, and 85.00%. The analysis of all false positive cases across the three diseases and their comparison with the final referral decisions revealed that only 17 patients were falsely referred among the 231 patients. The efficacy analysis of the system demonstrated the effectiveness of the AI grading process in the study's testing environment. Clinical staff involved in using the system provided positive feedback on the disease screening process, particularly praising the seamless workflow from patient registration to image transmission and obtaining the final result. Results from a questionnaire completed by 12 participants indicated that most found the system easy, quick, and highly satisfactory. The study also revealed room for improvement in the AMD model, suggesting the need to enhance its training data. Furthermore, the performance of the glaucoma model grading could be improved by incorporating additional measures such as intraocular pressure.

conclusionsThe implementation of the AI-based approach for screening three chronic eye diseases proved effective in real-world settings, earning positive feedback on the usability of the integrated platform from both the screening staff and auditors. The auditing function has proven valuable for obtaining efficient second opinions from experts, pointing to its potential for enhancing remote screening capabilities.

trial registrationInstitutional Review Board of the Hamburg Medical Chamber (Ethik-Kommission der Ärztekammer Hamburg): 2021-10574-BO-ff.

Indexed as

Diabetic RetinopathyGlaucomaMacular DegenerationArtificial IntelligenceHumansMass ScreeningSoftwareAMDArtificial intelligenceDiabetic retinopathyDigital color fundus imagingGlaucomaScreeningTelemedicine

Identifiers

PMID38302908
PMCPMC10832120
OpenAlexW4391437008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.